Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops

Kenji Inoue,1 Minako Shiokawa,1 Kyoko Ishida,2 Goji Tomita2 1Inouye Eye Hospital, Tokyo, Japan; 2Department of Ophthalmology, Toho University Ohashi Medical Center, Tokyo, Japan Purpose: To evaluate the safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% fixed-combination...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Inoue K, Shiokawa M, Ishida K, Tomita G
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/6dd7d8a0eb92405d94b1fe443bb15ba6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6dd7d8a0eb92405d94b1fe443bb15ba6
record_format	dspace
spelling	oai:doaj.org-article:6dd7d8a0eb92405d94b1fe443bb15ba62021-12-02T02:50:48ZSafety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops1177-5483https://doaj.org/article/6dd7d8a0eb92405d94b1fe443bb15ba62015-04-01T00:00:00Zhttp://www.dovepress.com/safety-and-efficacy-of-switching-from-dorzolamide-10timolol-maleate-05-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483 Kenji Inoue,1 Minako Shiokawa,1 Kyoko Ishida,2 Goji Tomita2 1Inouye Eye Hospital, Tokyo, Japan; 2Department of Ophthalmology, Toho University Ohashi Medical Center, Tokyo, Japan Purpose: To evaluate the safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% fixed-combination (DTFC) eye drops to brinzolamide 1.0%/timolol maleate 0.5% fixed-combination (BTFC) eye drops in patients with primary open-angle glaucoma or ocular hypertension. Methods: A total of 35 eyes of 35 patients with primary open-angle glaucoma or ocular hypertension using DTFC eye drops were included. Participants discontinued DTFC drops and immediately began using BTFC drops. All other eye drops currently being used were continued. Intraocular pressure (IOP) 1 and 3 months after switching medications was compared with baseline IOP. One month after switching medications, participant preference and adherence were evaluated. Adverse reactions were monitored at each study visit. Results: The IOP was 17.9±2.6 mmHg at baseline and 18.3±4.1 mmHg and 17.8±3.4 mmHg 1 month and 3 months after switching medications, respectively (P=0.633). The frequency of missing a dose was not different before (6.1%) and after (6.1%) switching to BTFC. Significantly fewer participants reported stinging after switching to BTFC (15.2%) than while using DTFC (51.5%, P<0.01). Blurred vision was reported with the same frequency before (39.4%) and after (42.4%) switching to BTFC. A total of 33.3% and 27.3% of patients preferred DTFC and BTFC, respectively. Several patients withdrew from the study because of discomfort (n=2, 5.7%), discharge (n=1, 2.9%), dizziness (n=1, 2.9%), or increased IOP (n=2, 5.7%). Conclusion: Switching from DTFC to BTFC was well tolerated and did not result in IOP changes or a decreased patient adherence. When glaucoma patients complain of stinging with DTFC administration, switching to BTFC is an acceptable treatment option. Keywords: brinzolamide/timolol fixed-combination, dorzolamide/timolol fixed-combination, intraocular pressure, switch, safetyInoue KShiokawa MIshida KTomita GDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2015, Iss default, Pp 619-623 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Inoue K Shiokawa M Ishida K Tomita G Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops
description	Kenji Inoue,1 Minako Shiokawa,1 Kyoko Ishida,2 Goji Tomita2 1Inouye Eye Hospital, Tokyo, Japan; 2Department of Ophthalmology, Toho University Ohashi Medical Center, Tokyo, Japan Purpose: To evaluate the safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% fixed-combination (DTFC) eye drops to brinzolamide 1.0%/timolol maleate 0.5% fixed-combination (BTFC) eye drops in patients with primary open-angle glaucoma or ocular hypertension. Methods: A total of 35 eyes of 35 patients with primary open-angle glaucoma or ocular hypertension using DTFC eye drops were included. Participants discontinued DTFC drops and immediately began using BTFC drops. All other eye drops currently being used were continued. Intraocular pressure (IOP) 1 and 3 months after switching medications was compared with baseline IOP. One month after switching medications, participant preference and adherence were evaluated. Adverse reactions were monitored at each study visit. Results: The IOP was 17.9±2.6 mmHg at baseline and 18.3±4.1 mmHg and 17.8±3.4 mmHg 1 month and 3 months after switching medications, respectively (P=0.633). The frequency of missing a dose was not different before (6.1%) and after (6.1%) switching to BTFC. Significantly fewer participants reported stinging after switching to BTFC (15.2%) than while using DTFC (51.5%, P<0.01). Blurred vision was reported with the same frequency before (39.4%) and after (42.4%) switching to BTFC. A total of 33.3% and 27.3% of patients preferred DTFC and BTFC, respectively. Several patients withdrew from the study because of discomfort (n=2, 5.7%), discharge (n=1, 2.9%), dizziness (n=1, 2.9%), or increased IOP (n=2, 5.7%). Conclusion: Switching from DTFC to BTFC was well tolerated and did not result in IOP changes or a decreased patient adherence. When glaucoma patients complain of stinging with DTFC administration, switching to BTFC is an acceptable treatment option. Keywords: brinzolamide/timolol fixed-combination, dorzolamide/timolol fixed-combination, intraocular pressure, switch, safety
format	article
author	Inoue K Shiokawa M Ishida K Tomita G
author_facet	Inoue K Shiokawa M Ishida K Tomita G
author_sort	Inoue K
title	Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops
title_short	Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops
title_full	Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops
title_fullStr	Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops
title_full_unstemmed	Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops
title_sort	safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/6dd7d8a0eb92405d94b1fe443bb15ba6
work_keys_str_mv	AT inouek safetyandefficacyofswitchingfromdorzolamide10timololmaleate05eyedropstobrinzolamide10timololmaleate05eyedrops AT shiokawam safetyandefficacyofswitchingfromdorzolamide10timololmaleate05eyedropstobrinzolamide10timololmaleate05eyedrops AT ishidak safetyandefficacyofswitchingfromdorzolamide10timololmaleate05eyedropstobrinzolamide10timololmaleate05eyedrops AT tomitag safetyandefficacyofswitchingfromdorzolamide10timololmaleate05eyedropstobrinzolamide10timololmaleate05eyedrops
_version_	1718402104879480832

Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops

Ejemplares similares